Equip a pharma (phase 1),ultra-rapid manufacturing of pharmaceuticals within abbreviated new drug application standards
Other Transaction IDV Awarded Last action
- Contract number
- HR00112490476
- Awardee
-
Mark Cuban Cost Plus Drug Company, PBC UEI N8P7MQ937WN7
- Awarding agency
-
Defense Advanced Research Projects Agency
Department of Defense
- Task orders
- 0
Award facts
- Last date to order
- Not on record
- IDV ceiling
- $14,510,582.00
- Contracting staff
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Competed Program Solicitation
- Pricing
- Other
Award details come from SAM.gov/FPDS.
About this IDV
The Defense Advanced Research Projects Agency awarded a multiple-award Other Transaction Indefinite Delivery Vehicle valued at $14.5 million to Mark Cuban Cost Plus Drug Company, PBC on August 9, 2024. This contract supports Phase 1 of the EQUIP-A-PHARMA (Ultra-Rapid Manufacturing of Pharmaceuticals) program, which focuses on developing innovative manufacturing capabilities for pharmaceutical products within Abbreviated New Drug Application standards. The award carries no small business or socioeconomic set-asides and establishes a framework through which task orders will be issued to develop and demonstrate rapid pharmaceutical manufacturing technologies and processes.
The EQUIP-A-PHARMA program aims to accelerate the production timeline for generic and biosimilar pharmaceutical products by establishing advanced manufacturing methodologies compliant with regulatory standards. Under this Other Transaction authority, Mark Cuban Cost Plus Drug Company will conduct research, development, and demonstration activities to create manufacturing approaches that significantly reduce the time required to bring pharmaceutical products to market. The indefinite delivery vehicle structure enables the government to issue multiple task orders as the program progresses, allowing for iterative development and scaling of manufacturing solutions while maintaining flexibility in execution and funding allocation throughout the performance period.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Additional Work (new agreement, FAR part 6 applies) | $513,137 | |
| Funding Only Action | $1,993,005 | |
| Exercise an Option | $11,507,940 | |
| Funding Only Action | $496,500 | |
| Other Administrative Action | -$496,500 | |
| Original award | $496,500 |
Quick answers
Who was awarded contract HR00112490476?
HR00112490476 was awarded to Mark Cuban Cost Plus Drug Company, PBC by Defense Advanced Research Projects Agency (Department of Defense) on August 9, 2024.
How much is contract HR00112490476 worth?
HR00112490476's own ceiling is $14,510,582.
Was contract HR00112490476 competed?
The extent of competition for HR00112490476 was competed.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV